SCHAUMBURG, Illinois, USA - American Pharmaceutical Partners, Inc (NASDAQ:APPX) and American Bioscience, Inc. (ABI) announced today that the U .S. Food and Drug Administration (FDA) have qualified ABRAXANETM all for Injectable Suspension (paclitaxel protein-bound particle for injectable suspension) (albumin-bound) contained via metastatic breast cancer. ABRAXANETM be signify for the exposure of breast cancer after last part of balance chemotherapy for metastatic bug or slip back in 6 months of adjuvant chemotherapy. Prior psychiatric therapy should particular incorporated an anthracycline unless clinically contraindicated.
With the prologue of levonorgestrel, Climara Pro is be a sign of for implement by mode of women with an intact uterus, whereas Climara is timely for women who fall over on have a hysterectomy.
ABRAXANE, consisting merely of albumin-bound paclitaxel nanoparticles, is purge of venomous solvents and demonstrated a person in charge rejoinder rate near an almost doubling of the reconciled target lesion response rate when compare with the solvent-based Taxol® in a prospectively randomized suit of 460 patients with metastatic breast cancer. Because it comprise no toxic solvents, this next-generation taxane article of art enable the charge of 50% more chemotherapy with a well-tolerated safekeeping profile, require no premedication to prevent hypersensitivity response and can be given ended 30 records using emblem IV tubing.
"ABRAXANE bring a much-needed new treatment judgment for women with metastatic breast cancer," said principal clinical trial investigator William J. Gradishar, M.D., Associate Professor of Medicine, Division of Hematology and Medical Oncology and Co-Director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital. "The pivotal clinical trial grades demonstrated that ABRAXANE have superior response rate when compared to Taxol in patients with metastatic breast cancer. For the first circumstance we be competent to submit patients the exhaustive cathartic benefits of paclitaxel. This create ABRAXANE a consequential fund in the approach we overegging the pudding breast cancer." "ABRAXANE has an superior therapeutic index compared to Taxol in the treatment of metastatic breast cancer base by its superior response rate and economically bracket for safety profile," said Joyce A. O'Shaughnessy, M.D., co-director, Breast Cancer Research, and Director, Breast Cancer Prevention, at Baylor-Charles A. Sammons Cancer Center in Dallas, TX. "Patients delivery Cremophor-based taxanes regrettably are discovered to toxicities cause by the solvent fairly than the swaying chemotherapy remedy. The patients with metastatic breast cancer who be treat with ABRAXANE not only achieve the superior response rate, but they also benefit from the certainty that ABRAXANE do not employment toxic solvents to deliver the active drug." "ABRAXANE is an certain therapeutic breakthrough since it is an active new class of drugs that address the toxicities associated with solvents in taxane-based chemotherapy, namely hypersensitivity reactions, inflexible myelosuppression, prolonged divergent neuropathy and severe edema," said Edith Perez, M.D., Professor of Medicine, Mayo Clinic College of Medicine, Chair Breast Committee, North Central Cancer Treatment Group. "Grade 4 neutropenia move a moment ago about off in slighter article than 10% of the patients. In the patients who industrialized Grade 3 peripheral neuropathy, nippy salvage occurred after a median of only 22 days. It is significant that ABRAXANE can be undamagingly administered to both youthful and elderly patients. Plans now are arranged to inspection this next-generation taxane in combination with other chemotherapeutic agents in the treatment of front-line metastatic breast cancer." "The designation of a new protein fragment drug class and the approval of ABRAXANE put pen to paper the culmination of over a decade of research in the science of albumin-bound nanoparticles by the ABI troop," said Patrick Soon-Shiong, M.D., Executive Chairman of American Pharmaceutical Partners and Chairman, President and Chief Executive Officer of American Bioscience. "We are gratified that our hard work will now plus breast cancer patients and are enthusiastic about the impending impact that the nab technology dais may have on the way we treat cancer and other disease." "We are over the moon to offer women with metastatic breast cancer a new, ultramodern treatment option, and this approval is a defining stumpy while for APP. We cry approval the constant efforts of the ABRAXANE team at ABI and APP, the clinical investigators, and the long-suffering participant in the trial who lend a hand shipping ABRAXANE to marketplace and make it unspoken for to treat women who are habitually facade with few option when they are diagnose with advanced breast cancer," said Al Heller, President and Chief Executive Officer of American Pharmaceutical Partners.